HPV-16 E7 is under clinical development by Gilead Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect HPV-16 E7’s likelihood of approval (LoA) and phase transition for Vaginal Cancer took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HPV-16 E7 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

HPV-16 E7 overview

Gene therapy is under development for the treatment of recurrent/refractory human papillomavirus induced cancers including cervical intraepithelial neoplasia, vaginal cancer, penile cancer, anal cancer and oropharyngeal cancer. The therapeutic candidate is administered by intravenous route and is comprised of autologous T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) protein.

It was also under development for cervical cancer, vulvar cancer (vulvar high-grade squamous intraepithelial lesions (HSIL)).

Gilead Sciences overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Quick View HPV-16 E7 LOA Data

Report Segments
  • Innovator
Drug Name
  • HPV-16 E7
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
  • Women’s Health
Key Developers
  • Sponsor Company: Gilead Sciences
  • Originator: U.S. National Institutes of Health
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.